Nuclear Medicine Radioisotopes Market by Isotope Function (Diagnostic Isotopes, Therapeutic Isotopes), Mode Of Administration (Intravenous Injection, Oral Ingestion), Production Technology, End User, Disease Area - Global Forecast 2025-2032
Description
The Nuclear Medicine Radioisotopes Market was valued at USD 6.30 billion in 2024 and is projected to grow to USD 6.89 billion in 2025, with a CAGR of 9.92%, reaching USD 13.44 billion by 2032.
A forward-looking introduction framing the scientific advances, clinical adoption drivers, supply chain fragility, and regulatory pressures reshaping nuclear medicine radioisotopes
Nuclear medicine radioisotopes are at the intersection of molecular science, clinical practice, and distribution complexity, and this introduction frames the principal forces shaping the domain. Recent advances in radiochemistry, imaging hardware, and theranostics have transformed diagnostic pathways and therapeutic options, prompting multidisciplinary collaboration among academic centers, commercial developers, and healthcare providers. At the same time, supply chain fragility, evolving regulatory expectations, and shifting reimbursement landscapes have elevated strategic risk for stakeholders across the value chain.
As you progress from foundational knowledge to operational strategy, it is important to appreciate how scientific innovation translates into practical deployment. Improvements in isotope production technologies such as cyclotron and generator systems, paired with better radiopharmaceutical targeting mechanisms, are enabling more precise imaging and targeted treatments. However, clinical adoption requires alignment among clinical guidelines, training pathways, and logistical capabilities that ensure patient access. By situating technical potential alongside systemic constraints, this introduction sets the stage for a nuanced discussion of transformative trends, policy impacts, segmentation insights, regional dynamics, company behaviors, and practical recommendations that follow.
An authoritative synthesis of the transformative technological, clinical, regulatory, and commercial shifts that are redefining nuclear medicine radioisotope development and delivery
The landscape of nuclear medicine is undergoing transformative shifts driven by technological convergence, clinical evidence, and new commercial models that collectively redefine opportunity and risk. On the technological front, improvements in PET imaging resolution, novel radiolabeling chemistries, and automated synthesis platforms are reducing production complexity and expanding the range of viable radiopharmaceuticals. Concurrently, the maturation of theranostic paradigms-where diagnostic imaging directly informs targeted radionuclide therapy-has created integrated clinical pathways that accelerate patient selection and treatment monitoring.
Commercially, partnerships between imaging centers, specialty pharmacies, and logistics providers are emerging to address the need for reliable cold-chain delivery and just-in-time manufacturing. These operational arrangements are supported by an expanding evidence base demonstrating clinical benefit in selected indications, which in turn influences payer deliberations and guideline committees. Regulatory agencies are adapting by clarifying pathways for both diagnostics and therapeutics, emphasizing quality systems, traceability, and patient safety. Together, these shifts are fostering a more systematized ecosystem where scientific potential is increasingly translatable into reproducible clinical outcomes, while also raising expectations for coordinated governance, workforce training, and supply resilience.
A precise examination of how tariff measures in 2025 have altered sourcing, logistics, and procurement behaviors while accelerating interest in domestic and regional production resilience
The imposition of United States tariffs in 2025 introduced notable complexity into the procurement and international movement of medical isotopes, raw materials, and specialized equipment. Tariff measures have reverberated through established supply chains by increasing landed costs for imported components, prompting suppliers and providers to reassess sourcing strategies and contract terms. In response, some manufacturers have pursued nearshoring or regionalized production to mitigate exposure to cross-border levies and transit-related uncertainties, while logistics partners have introduced new routing and documentation solutions to preserve delivery timelines.
In healthcare settings, procurement teams have been compelled to negotiate longer-term agreements and to examine total cost of ownership rather than unit pricing alone, given the added volatility in import costs. Regulatory authorities and customs agencies have intensified scrutiny of medical imports to ensure compliance with tariff classifications and health safeguards, creating incremental administrative burden for exporters and importers. Importantly, these dynamics have reinforced the strategic value of domestic production capacity for key radioisotopes and critical components, encouraging investment in scalable, compliant manufacturing platforms. Transitioning from immediate cost-containment tactics to systemic resilience planning will remain essential as stakeholders balance clinical imperatives with the operational realities introduced by tariff-related interventions.
Detailed segmentation-driven insights clarifying how diagnostic PET and SPECT tracers versus targeted therapeutic radionuclide treatments create distinct clinical, manufacturing, and commercial imperatives
A meaningful assessment of the radioisotope space requires disaggregation by product type and use case to align development and commercialization strategies with clinical pathways. Based on radiopharmaceuticals, the market is studied across diagnostic agents and therapeutic agents; the diagnostic agents split into PET agents and SPECT agents, with PET agents further characterized by F-18 FDG and F-18 PSMA as prominent tracers used for metabolic and prostate-specific imaging respectively. The therapeutic agents category encompasses peptide receptor radionuclide therapy, radioembolization, and radioimmunotherapy, each representing distinct mechanisms, clinical indications, and production logistics that influence stakeholder priorities.
This segmentation highlights how diagnostic tracers tend to demand high-frequency, time-sensitive logistics and routine manufacturing throughput, whereas therapeutic agents often require centralized specialized production, complex dosimetry, and integrated clinical support for administration and adverse-event management. Consequently, clinical adoption cycles, regulatory dossiers, and payer engagement strategies differ across these segments. Portfolio and pipeline decisions should therefore be informed by the operational realities intrinsic to each category, including supply chain lead times, clinical training requirements, and the interplay between imaging diagnostics and therapeutic follow-through that underpins successful theranostic programs.
A comparative regional analysis revealing how distinct healthcare systems, regulatory frameworks, and infrastructure levels drive varied adoption pathways for radioisotopes across global markets
Regional dynamics shape how technologies are developed, regulated, and delivered, and understanding geographic distinctions is essential for effective market entry and partnership decisions. In the Americas, there is a concentration of advanced clinical programs, integrated reimbursement pathways in some health systems, and a growing emphasis on domestic production to reduce import risk, which together create fertile ground for ambitious theranostic initiatives. In Europe, the Middle East & Africa, regulatory harmonization efforts and pan-regional distribution hubs interact with variable healthcare infrastructure, producing differentiated adoption curves where centers of excellence lead early clinical implementation while wider access builds more slowly.
Across the Asia-Pacific region, rapid investment in imaging infrastructure, expanding clinical trial activity, and targeted national strategies for biotech innovation are driving adoption of novel radiopharmaceuticals, although logistics complexities and regulatory heterogeneity require localized commercialization plans. Cross-regionally, collaboration among manufacturers, logistics providers, clinical networks, and regulators has emerged as a practical mechanism to align standards, reduce duplication, and accelerate knowledge transfer, thereby enabling scalable models of care anchored in both clinical evidence and sustainable supply-chain design.
Insightful overview of how leading companies combine proprietary radiochemistry, resilient operations, and strategic partnerships to secure clinical and commercial advantages in radioisotopes
Key company behavior in the radioisotope ecosystem reflects an interplay between innovation, operational excellence, and strategic partnerships that together determine competitive positioning. Organizations leading in radiochemistry and clinical development are differentiating through proprietary labeling methods, scalable synthesis platforms, and targeted clinical pipelines that demonstrate clear patient benefit. Meanwhile, specialized manufacturers and logistics firms are investing in temperature-controlled distribution networks, redundant production capabilities, and validation processes to support just-in-time delivery and reduce the clinical impact of supply interruptions.
Strategic alliances between device makers, pharmaceutical developers, and healthcare providers are becoming more commonplace, enabling integrated solutions that combine imaging agents, hardware, and software to enhance diagnostic precision and facilitate therapy planning. Companies are also prioritizing regulatory affairs expertise and health economics evidence generation to expedite market access and reimbursement conversations. Overall, competitive advantage is increasingly rooted in the ability to orchestrate complex technical capabilities with reliable operations and evidence-based clinical value propositions.
Practical and prioritized recommendations for executives to strengthen production resilience, forge strategic partnerships, generate compelling clinical evidence, and mitigate supply and policy risks
Industry leaders should pursue a set of actionable initiatives to translate emerging scientific and market intelligence into operational strength and clinical impact. First, invest in modular, scalable production and redundancy mechanisms that reduce the risk of supply disruption while enabling flexible response to clinical demand. Second, forge targeted partnerships across clinical networks, specialty pharmacies, and logistics providers to create end-to-end delivery models that support timely imaging and treatment. Third, prioritize evidence generation that links diagnostic precision to therapeutic outcomes and that addresses payer and guideline-making bodies’ requirements for clinical utility.
In addition, organizations should develop regulatory and quality portfolios that anticipate evolving standards for radiopharmaceutical manufacturing and distribution, while fostering workforce development programs to ensure competent multispecialty teams for administration and patient management. Finally, adopt scenario-based procurement and contracting approaches that internalize tariff and trade risks while aligning incentives among manufacturers, payers, and providers. These actions, taken in combination, will help leaders secure reliable access, demonstrate comparative clinical value, and scale sustainable business models across variable regional environments.
Transparent, multi-source research methodology combining expert interviews, peer-reviewed evidence, regulatory review, and scenario analysis to validate strategic insights and operational recommendations
The research methodology underpinning this analysis integrates qualitative and quantitative evidence sources, expert consultation, and triangulation across technical, clinical, and operational domains. Primary inputs included structured interviews with clinicians, manufacturing leaders, regulatory specialists, and logistics partners to capture first-hand perspectives on clinical needs, production constraints, and distribution realities. Secondary sources comprised peer-reviewed literature, regulatory guidance documents, industry technical standards, and public statements that clarify technological capabilities and policy trends.
Synthesis involved mapping clinical use cases to manufacturing modalities and logistics requirements, followed by scenario analysis to explore the operational impact of supply shocks and policy changes. Throughout, data validation steps were applied to reconcile divergent stakeholder views and to ensure robust interpretation of trends. This layered approach emphasizes transparency in assumptions, replicable methods for segment-level analysis, and practical linkage between evidence and recommendations for decision-makers involved in development, procurement, and clinical deployment.
A conclusive synthesis emphasizing the need to pair scientific innovation with operational resilience and strategic partnerships to realize the clinical promise of radioisotopes
In conclusion, the nuclear medicine radioisotope field is characterized by rapid scientific progress coupled with systemic challenges that require integrated solutions. Technological innovation in tracers and synthesis is expanding clinical possibilities, while theranostic approaches are tightening the link between diagnosis and targeted therapy. At the same time, supply-chain vulnerabilities, tariff-induced cost pressures, and diverse regional regulatory regimes underscore the need for resilient manufacturing strategies, deliberate partnership formation, and proactive evidence generation to achieve sustainable clinical adoption.
Decision-makers should therefore adopt a dual emphasis: pursue innovation that delivers clear patient benefit and reinforce operational foundations that ensure consistent, compliant access. By doing so, organizations can translate promising scientific developments into measurable improvements in patient care, while maintaining the flexibility to navigate policy shifts and market complexities. This balanced approach will be essential for sustaining momentum in a sector that sits at the cutting edge of personalized diagnostic and therapeutic medicine.
Note: PDF & Excel + Online Access - 1 Year
A forward-looking introduction framing the scientific advances, clinical adoption drivers, supply chain fragility, and regulatory pressures reshaping nuclear medicine radioisotopes
Nuclear medicine radioisotopes are at the intersection of molecular science, clinical practice, and distribution complexity, and this introduction frames the principal forces shaping the domain. Recent advances in radiochemistry, imaging hardware, and theranostics have transformed diagnostic pathways and therapeutic options, prompting multidisciplinary collaboration among academic centers, commercial developers, and healthcare providers. At the same time, supply chain fragility, evolving regulatory expectations, and shifting reimbursement landscapes have elevated strategic risk for stakeholders across the value chain.
As you progress from foundational knowledge to operational strategy, it is important to appreciate how scientific innovation translates into practical deployment. Improvements in isotope production technologies such as cyclotron and generator systems, paired with better radiopharmaceutical targeting mechanisms, are enabling more precise imaging and targeted treatments. However, clinical adoption requires alignment among clinical guidelines, training pathways, and logistical capabilities that ensure patient access. By situating technical potential alongside systemic constraints, this introduction sets the stage for a nuanced discussion of transformative trends, policy impacts, segmentation insights, regional dynamics, company behaviors, and practical recommendations that follow.
An authoritative synthesis of the transformative technological, clinical, regulatory, and commercial shifts that are redefining nuclear medicine radioisotope development and delivery
The landscape of nuclear medicine is undergoing transformative shifts driven by technological convergence, clinical evidence, and new commercial models that collectively redefine opportunity and risk. On the technological front, improvements in PET imaging resolution, novel radiolabeling chemistries, and automated synthesis platforms are reducing production complexity and expanding the range of viable radiopharmaceuticals. Concurrently, the maturation of theranostic paradigms-where diagnostic imaging directly informs targeted radionuclide therapy-has created integrated clinical pathways that accelerate patient selection and treatment monitoring.
Commercially, partnerships between imaging centers, specialty pharmacies, and logistics providers are emerging to address the need for reliable cold-chain delivery and just-in-time manufacturing. These operational arrangements are supported by an expanding evidence base demonstrating clinical benefit in selected indications, which in turn influences payer deliberations and guideline committees. Regulatory agencies are adapting by clarifying pathways for both diagnostics and therapeutics, emphasizing quality systems, traceability, and patient safety. Together, these shifts are fostering a more systematized ecosystem where scientific potential is increasingly translatable into reproducible clinical outcomes, while also raising expectations for coordinated governance, workforce training, and supply resilience.
A precise examination of how tariff measures in 2025 have altered sourcing, logistics, and procurement behaviors while accelerating interest in domestic and regional production resilience
The imposition of United States tariffs in 2025 introduced notable complexity into the procurement and international movement of medical isotopes, raw materials, and specialized equipment. Tariff measures have reverberated through established supply chains by increasing landed costs for imported components, prompting suppliers and providers to reassess sourcing strategies and contract terms. In response, some manufacturers have pursued nearshoring or regionalized production to mitigate exposure to cross-border levies and transit-related uncertainties, while logistics partners have introduced new routing and documentation solutions to preserve delivery timelines.
In healthcare settings, procurement teams have been compelled to negotiate longer-term agreements and to examine total cost of ownership rather than unit pricing alone, given the added volatility in import costs. Regulatory authorities and customs agencies have intensified scrutiny of medical imports to ensure compliance with tariff classifications and health safeguards, creating incremental administrative burden for exporters and importers. Importantly, these dynamics have reinforced the strategic value of domestic production capacity for key radioisotopes and critical components, encouraging investment in scalable, compliant manufacturing platforms. Transitioning from immediate cost-containment tactics to systemic resilience planning will remain essential as stakeholders balance clinical imperatives with the operational realities introduced by tariff-related interventions.
Detailed segmentation-driven insights clarifying how diagnostic PET and SPECT tracers versus targeted therapeutic radionuclide treatments create distinct clinical, manufacturing, and commercial imperatives
A meaningful assessment of the radioisotope space requires disaggregation by product type and use case to align development and commercialization strategies with clinical pathways. Based on radiopharmaceuticals, the market is studied across diagnostic agents and therapeutic agents; the diagnostic agents split into PET agents and SPECT agents, with PET agents further characterized by F-18 FDG and F-18 PSMA as prominent tracers used for metabolic and prostate-specific imaging respectively. The therapeutic agents category encompasses peptide receptor radionuclide therapy, radioembolization, and radioimmunotherapy, each representing distinct mechanisms, clinical indications, and production logistics that influence stakeholder priorities.
This segmentation highlights how diagnostic tracers tend to demand high-frequency, time-sensitive logistics and routine manufacturing throughput, whereas therapeutic agents often require centralized specialized production, complex dosimetry, and integrated clinical support for administration and adverse-event management. Consequently, clinical adoption cycles, regulatory dossiers, and payer engagement strategies differ across these segments. Portfolio and pipeline decisions should therefore be informed by the operational realities intrinsic to each category, including supply chain lead times, clinical training requirements, and the interplay between imaging diagnostics and therapeutic follow-through that underpins successful theranostic programs.
A comparative regional analysis revealing how distinct healthcare systems, regulatory frameworks, and infrastructure levels drive varied adoption pathways for radioisotopes across global markets
Regional dynamics shape how technologies are developed, regulated, and delivered, and understanding geographic distinctions is essential for effective market entry and partnership decisions. In the Americas, there is a concentration of advanced clinical programs, integrated reimbursement pathways in some health systems, and a growing emphasis on domestic production to reduce import risk, which together create fertile ground for ambitious theranostic initiatives. In Europe, the Middle East & Africa, regulatory harmonization efforts and pan-regional distribution hubs interact with variable healthcare infrastructure, producing differentiated adoption curves where centers of excellence lead early clinical implementation while wider access builds more slowly.
Across the Asia-Pacific region, rapid investment in imaging infrastructure, expanding clinical trial activity, and targeted national strategies for biotech innovation are driving adoption of novel radiopharmaceuticals, although logistics complexities and regulatory heterogeneity require localized commercialization plans. Cross-regionally, collaboration among manufacturers, logistics providers, clinical networks, and regulators has emerged as a practical mechanism to align standards, reduce duplication, and accelerate knowledge transfer, thereby enabling scalable models of care anchored in both clinical evidence and sustainable supply-chain design.
Insightful overview of how leading companies combine proprietary radiochemistry, resilient operations, and strategic partnerships to secure clinical and commercial advantages in radioisotopes
Key company behavior in the radioisotope ecosystem reflects an interplay between innovation, operational excellence, and strategic partnerships that together determine competitive positioning. Organizations leading in radiochemistry and clinical development are differentiating through proprietary labeling methods, scalable synthesis platforms, and targeted clinical pipelines that demonstrate clear patient benefit. Meanwhile, specialized manufacturers and logistics firms are investing in temperature-controlled distribution networks, redundant production capabilities, and validation processes to support just-in-time delivery and reduce the clinical impact of supply interruptions.
Strategic alliances between device makers, pharmaceutical developers, and healthcare providers are becoming more commonplace, enabling integrated solutions that combine imaging agents, hardware, and software to enhance diagnostic precision and facilitate therapy planning. Companies are also prioritizing regulatory affairs expertise and health economics evidence generation to expedite market access and reimbursement conversations. Overall, competitive advantage is increasingly rooted in the ability to orchestrate complex technical capabilities with reliable operations and evidence-based clinical value propositions.
Practical and prioritized recommendations for executives to strengthen production resilience, forge strategic partnerships, generate compelling clinical evidence, and mitigate supply and policy risks
Industry leaders should pursue a set of actionable initiatives to translate emerging scientific and market intelligence into operational strength and clinical impact. First, invest in modular, scalable production and redundancy mechanisms that reduce the risk of supply disruption while enabling flexible response to clinical demand. Second, forge targeted partnerships across clinical networks, specialty pharmacies, and logistics providers to create end-to-end delivery models that support timely imaging and treatment. Third, prioritize evidence generation that links diagnostic precision to therapeutic outcomes and that addresses payer and guideline-making bodies’ requirements for clinical utility.
In addition, organizations should develop regulatory and quality portfolios that anticipate evolving standards for radiopharmaceutical manufacturing and distribution, while fostering workforce development programs to ensure competent multispecialty teams for administration and patient management. Finally, adopt scenario-based procurement and contracting approaches that internalize tariff and trade risks while aligning incentives among manufacturers, payers, and providers. These actions, taken in combination, will help leaders secure reliable access, demonstrate comparative clinical value, and scale sustainable business models across variable regional environments.
Transparent, multi-source research methodology combining expert interviews, peer-reviewed evidence, regulatory review, and scenario analysis to validate strategic insights and operational recommendations
The research methodology underpinning this analysis integrates qualitative and quantitative evidence sources, expert consultation, and triangulation across technical, clinical, and operational domains. Primary inputs included structured interviews with clinicians, manufacturing leaders, regulatory specialists, and logistics partners to capture first-hand perspectives on clinical needs, production constraints, and distribution realities. Secondary sources comprised peer-reviewed literature, regulatory guidance documents, industry technical standards, and public statements that clarify technological capabilities and policy trends.
Synthesis involved mapping clinical use cases to manufacturing modalities and logistics requirements, followed by scenario analysis to explore the operational impact of supply shocks and policy changes. Throughout, data validation steps were applied to reconcile divergent stakeholder views and to ensure robust interpretation of trends. This layered approach emphasizes transparency in assumptions, replicable methods for segment-level analysis, and practical linkage between evidence and recommendations for decision-makers involved in development, procurement, and clinical deployment.
A conclusive synthesis emphasizing the need to pair scientific innovation with operational resilience and strategic partnerships to realize the clinical promise of radioisotopes
In conclusion, the nuclear medicine radioisotope field is characterized by rapid scientific progress coupled with systemic challenges that require integrated solutions. Technological innovation in tracers and synthesis is expanding clinical possibilities, while theranostic approaches are tightening the link between diagnosis and targeted therapy. At the same time, supply-chain vulnerabilities, tariff-induced cost pressures, and diverse regional regulatory regimes underscore the need for resilient manufacturing strategies, deliberate partnership formation, and proactive evidence generation to achieve sustainable clinical adoption.
Decision-makers should therefore adopt a dual emphasis: pursue innovation that delivers clear patient benefit and reinforce operational foundations that ensure consistent, compliant access. By doing so, organizations can translate promising scientific developments into measurable improvements in patient care, while maintaining the flexibility to navigate policy shifts and market complexities. This balanced approach will be essential for sustaining momentum in a sector that sits at the cutting edge of personalized diagnostic and therapeutic medicine.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
196 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Expansion of gallium-68 production capacity to meet growing theranostics demand
- 5.2. Adoption of lutetium-177 targeted radioligand therapies for advanced prostate cancer imaging
- 5.3. Supply chain resilience initiatives for molybdenum-99 and technetium-99m radioisotopes
- 5.4. Emerging cyclotron-based production of iodine-123 to reduce reactor dependence
- 5.5. Regulatory harmonization efforts for fast-track approval of novel nuclear medicine isotopes
- 5.6. Integration of artificial intelligence for optimized radiopharmaceutical dose calculation in clinical workflows
- 5.7. Development of copper-64 labeled PET tracers for enhanced cancer imaging specificity
- 5.8. Investment trends in decentralized on-site radioisotope generator installations by major health systems
- 5.9. Collaborative partnerships between biotech companies and nuclear facilities driving isotope innovation
- 5.10. Growth of alpha-emitting targeted therapies using actinium-225 and lead-212 in oncology applications
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Nuclear Medicine Radioisotopes Market, by Isotope Function
- 8.1. Diagnostic Isotopes
- 8.1.1. SPECT Isotopes
- 8.1.1.1. Technetium-99m (Tc-99m)
- 8.1.1.2. Iodine-123 (I-123)
- 8.1.1.3. Thallium-201 (Tl-201)
- 8.1.1.4. Gallium-67 (Ga-67)
- 8.1.1.5. Indium-111 (In-111)
- 8.1.2. PET Isotopes
- 8.1.2.1. Fluorine-18 (F-18)
- 8.1.2.2. Carbon-11 (C-11)
- 8.1.2.3. Nitrogen-13 (N-13)
- 8.1.2.4. Oxygen-15 (O-15)
- 8.1.2.5. Rubidium-82 (Rb-82)
- 8.1.2.6. Copper-64 (Cu-64)
- 8.2. Therapeutic Isotopes
- 8.2.1. Beta Emitters
- 8.2.2. Alpha Emitters
- 8.2.3. Auger Electron Emitters
- 8.2.4. Brachytherapy Isotopes
- 9. Nuclear Medicine Radioisotopes Market, by Mode Of Administration
- 9.1. Intravenous Injection
- 9.2. Oral Ingestion
- 10. Nuclear Medicine Radioisotopes Market, by Production Technology
- 10.1. Nuclear Reactor Production
- 10.2. Cyclotron Production
- 10.3. Generator Systems
- 10.4. Linear Accelerator Production
- 11. Nuclear Medicine Radioisotopes Market, by End User
- 11.1. Academic & Research Institutes
- 11.2. Diagnostic Imaging Centers
- 11.3. Hospitals
- 11.4. Pharmaceutical & Biotechnology Companies
- 12. Nuclear Medicine Radioisotopes Market, by Disease Area
- 12.1. Oncology
- 12.2. Cardiology
- 12.3. Neurology
- 12.4. Endocrinology
- 12.5. Pulmonology
- 12.6. Nephrology
- 12.7. Gastroenterology
- 12.8. Infection And Inflammation
- 13. Nuclear Medicine Radioisotopes Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Nuclear Medicine Radioisotopes Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Nuclear Medicine Radioisotopes Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Curium Pharma
- 16.3.2. China Isotope & Radiation Corporation
- 16.3.3. BWX Technologies Inc
- 16.3.4. Cardinal Health
- 16.3.5. Eckert & Ziegler AG
- 16.3.6. GE HealthCare Technologies Inc
- 16.3.7. Ionetix Corporation
- 16.3.8. IRE ELiT
- 16.3.9. ISOFLEX USA
- 16.3.10. ITM Isotope Technologies Munich SE
- 16.3.11. Life Molecular Imaging
- 16.3.12. NECSA Ltd
- 16.3.13. NorthStar Medical Radioisotopes LLC
- 16.3.14. NTP Radioisotopes SOC Ltd
- 16.3.15. Nusano
- 16.3.16. Orano Med
- 16.3.17. SOFIE Biosciences Inc
- 16.3.18. Telix Pharmaceuticals Ltd
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
